Inari Medical, Inc. (NASDAQ:NARI) Director Donald B. Milder Sells 7,000 Shares

Inari Medical, Inc. (NASDAQ:NARIGet Rating) Director Donald B. Milder sold 7,000 shares of Inari Medical stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $80.25, for a total value of $561,750.00. Following the completion of the sale, the director now directly owns 3,199,614 shares of the company’s stock, valued at approximately $256,769,023.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Inari Medical Stock Down 5.6 %

Shares of NASDAQ NARI opened at $69.60 on Friday. The company has a market cap of $3.72 billion, a P/E ratio of -240.00 and a beta of 1.49. The business has a 50-day simple moving average of $75.43 and a two-hundred day simple moving average of $75.56. Inari Medical, Inc. has a 52 week low of $50.50 and a 52 week high of $100.00.

Inari Medical (NASDAQ:NARIGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. The firm had revenue of $92.74 million during the quarter, compared to the consensus estimate of $88.04 million. Inari Medical had a negative return on equity of 4.60% and a negative net margin of 4.47%. Equities research analysts anticipate that Inari Medical, Inc. will post -0.67 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Canaccord Genuity Group lifted their price objective on Inari Medical from $92.00 to $94.00 and gave the stock a “buy” rating in a report on Friday. Canaccord Genuity Group lifted their price objective on Inari Medical from $92.00 to $94.00 and gave the stock a “buy” rating in a report on Friday. Morgan Stanley decreased their price objective on Inari Medical from $108.00 to $93.00 and set an “overweight” rating for the company in a report on Friday, July 15th. BTIG Research decreased their price objective on Inari Medical from $130.00 to $100.00 and set a “buy” rating for the company in a report on Friday, June 24th. Finally, Truist Financial started coverage on Inari Medical in a research note on Monday, September 12th. They issued a “hold” rating and a $87.00 target price for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.71.

Institutional Trading of Inari Medical

Large investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its position in Inari Medical by 46.8% in the 1st quarter. Wellington Management Group LLP now owns 4,626,607 shares of the company’s stock worth $419,355,000 after buying an additional 1,475,313 shares during the last quarter. Vanguard Group Inc. lifted its position in Inari Medical by 13.4% in the 1st quarter. Vanguard Group Inc. now owns 3,518,646 shares of the company’s stock worth $318,930,000 after buying an additional 416,425 shares during the last quarter. Capital International Investors lifted its position in Inari Medical by 0.8% in the 1st quarter. Capital International Investors now owns 2,838,045 shares of the company’s stock worth $257,240,000 after buying an additional 22,159 shares during the last quarter. Alliancebernstein L.P. lifted its position in Inari Medical by 17.2% in the 4th quarter. Alliancebernstein L.P. now owns 2,777,274 shares of the company’s stock worth $253,482,000 after buying an additional 407,400 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Inari Medical by 22.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,966,302 shares of the company’s stock worth $133,689,000 after buying an additional 356,309 shares during the last quarter. Institutional investors own 84.11% of the company’s stock.

About Inari Medical

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.

Read More

Insider Buying and Selling by Quarter for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.